興科蓉醫藥：2023中期報告.pdf

1、2023 INTERIM REPORT 中期報告Sinco Pharmaceuticals Holdings Limited 兴科蓉医药控股有限公司2023 Interim Report 中期報告Contents目錄2Corporate Information公司資料4Financial Highlights財務摘要6Corporate Profile公司簡介7Management Discussion and Analysis管理層討論及分析23Other Information其他資料32Independent Review Report獨立審閱報告34Interim Condensed

2、Consolidated Statement of Profit or Loss and Other Comprehensive Income中期簡明綜合損益及其他全面收益表35Interim Condensed Consolidated Statement of Financial Position中期簡明綜合財務狀況表37Interim Condensed Consolidated Statement of Changes in Equity中期簡明綜合權益變動表38Interim Condensed Consolidated Statement of Cash Flows中期簡明綜合現金

3、流量表40Notes to Interim Condensed Financial Information中期簡明財務資料附註70Definitions釋義Corporate Information公司資料2Sinco Pharmaceuticals Holdings Limited Interim Report 2023BOARD OF DIRECTORSExecutive DirectorsMr.Huang Xiangbin(Chairman)Mr.Lei Shifeng(appointed with effect from 29 March 2023)Independent Non-ex

4、ecutive DirectorsMr.Lau Ying KitMr.Liu WenfangMr.Wang QingMr.Bai ZhizhongAUDIT COMMITTEEMr.Lau Ying Kit(Chairman)Mr.Liu WenfangMr.Wang QingMr.Bai ZhizhongREMUNERATION COMMITTEEMr.Wang Qing(Chairman)Mr.Liu WenfangMr.Bai ZhizhongMr.Lei Shifeng(appointed with effect from 29 March 2023)NOMINATION COMMIT

5、TEEMr.Huang Xiangbin(Chairman)Mr.Liu WenfangMr.Lau Ying KitINTERNAL CONTROL AND CORPORATE GOVERNANCE COMMITTEEMr.Lau Ying Kit(Chairman)Mr.Wang QingMr.Liu WenfangMr.Bai ZhizhongMr.Lei Shifeng(appointed with effect from 29 March 2023)AUTHORISED REPRESENTATIVESMr.Huang XiangbinMr.Li Kin WaiJOINT COMPAN

6、Y SECRETARIESMs.Peng YunluMr.Li Kin WaiREGISTERED OFFICEPO Box 309Ugland HouseGrand Cayman,KY1-1104Cayman Islands董事會執行董事黃祥彬先生（主席）雷世鋒先生（於2023年3月29日獲委任）獨立非執行董事劉英傑先生劉文芳先生汪晴先生白志中先生審核委員會劉英傑先生（主席）劉文芳先生汪晴先生白志中先生薪酬委員會汪晴先生（主席）劉文芳先生白志中先生雷世鋒先生（於2023年3月29日獲委任）提名委員會黃祥彬先生（主席）劉文芳先生劉英傑先生內部控制及企業管治委員會劉英傑先生（主席）汪晴先生劉文芳